BRIEF—Novo Nordisk to test obesity drugs including Wegovy in alcohol use

Danish diabetes and obesity giant Novo Nordisk is planning to test whether its weight loss drugs, including semaglutide, marketed as Wegovy, can impact alcohol use in patients with liver disease, according to an update the company has posted on a federal registry of clinical trials, and reported by Bloomberg.

The nine-month Phase II trial is designed to evaluate Novo Nordisk's Food and Drug Administration (FDA)-approved obesity therapy, semaglutide, and its experimental obesity therapy, CagriSema, a combination of semaglutide and an amylin analog called cagrilintide.

Bloomberg cited the company’s global development chief, Martin Holst Lange, as saying that the company will also test an early-stage asset targeting a hormone called fibroblast growth factor 21 as part of the study.